Best objective response with venetoclax monotherapy, as assessed by the investigator
| . | Patients who received idelalisib as the last prior BCRi . | ||
|---|---|---|---|
| Main cohort (n = 21) . | Expansion cohort (n = 15) . | All patients (N = 36) . | |
| Time on venetoclax, median (range), months | 20 (1-29) | 10 (2-16) | 14 (1-29) |
| ORR | 14 (67) | 10 (67) | 24 (67) |
| CR/Cri | 2 (10)/1 (5) | 0/0 | 2 (6)/1 (3) |
| nPR | 0 | 0 | 0 |
| PR | 11 (52) | 10 (67) | 21 (58) |
| SD | 6 (29) | 4 (27) | 10 (28) |
| PD | 1 (5) | 1 (7) | 2* (6) |
| . | Patients who received idelalisib as the last prior BCRi . | ||
|---|---|---|---|
| Main cohort (n = 21) . | Expansion cohort (n = 15) . | All patients (N = 36) . | |
| Time on venetoclax, median (range), months | 20 (1-29) | 10 (2-16) | 14 (1-29) |
| ORR | 14 (67) | 10 (67) | 24 (67) |
| CR/Cri | 2 (10)/1 (5) | 0/0 | 2 (6)/1 (3) |
| nPR | 0 | 0 | 0 |
| PR | 11 (52) | 10 (67) | 21 (58) |
| SD | 6 (29) | 4 (27) | 10 (28) |
| PD | 1 (5) | 1 (7) | 2* (6) |
ORR = complete remission (CR) + CR with incomplete bone marrow recovery (CRi) + nodular partial remission (nPR) + PR.
CLL progressed, and the patient discontinued because of progression.